Communications medicine · 2025
Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yudina Anastasiya, Tazearslan Cagdas, Baisangurov Artur, Nuzhdina Ekaterina, Lauziere Kelley, Segodin Vitaly, Podsvirova Svetlana, Starikov Sergey, Chasse Madison, Shaposhnikov Kirill, Kaneunyenye Leznath, Klimchuk Olesia, Kuzkina Natalia, English Noel, Khegai Gleb, Sookiasian Danielle, Shafranskaya Daria, Fernandez Dawn, Lozinsky Yaroslav, Sobolev Andrew, Abdou Mary, Turova Polina, Chernyshov Konstantin, Efremov Alexey, Andrewes Samuel, Feinberg Aviva, McKenna Brianna, Brown Jessica H, Love Anna, Curran John, Lennerz Jochen, Bagaev Alexander
Аннотация
BACKGROUND: Combining RNA sequencing (RNA-seq) with whole exome sequencing (WES) from a single tumor sample can substantially improve the detection of clinically relevant alterations in cancer. However, routine clinical adoption of this integrated approach remains limited, especially for RNA-seq, due to the absence of standardized validation frameworks.
METHODS: We developed and validated an assay that integrates RNA-seq and WES for evaluating gene expression, gene fusions, tumor microenvironment signatures, somatic single nucleotide variants (SNVs), insertions/deletions (INDELs), and copy number variations (CNVs). Exome-wide somatic reference standards were generated to support analytical validation using multiple sequencing runs of cell lines at varying purities.
RESULTS: Assay validation involves 3 steps: (1) analytical validation using custom reference samples containing 3042 SNVs and 47,466 CNVs; (2) orthogonal testing in patient samples; and (3) assessment of clinical utility in real-world cases. Applied to 2230 clinical tumor samples, the integrated assay enables direct correlation of somatic alterations with gene expression, recovery of variants missed by DNA-only testing, and improves detection of gene fusions. In addition to uncovering clinically actionable alterations in 98% of cases, the assay also reveals complex genomic rearrangements that would likely have remained undetected without RNA data.
CONCLUSIONS: This study provides practical validation guidelines for integrated RNA and DNA sequencing in clinical oncology. The combined assay enhances the detection of actionable alterations, thereby facilitating personalized treatment strategies for cancer patients.
METHODS: We developed and validated an assay that integrates RNA-seq and WES for evaluating gene expression, gene fusions, tumor microenvironment signatures, somatic single nucleotide variants (SNVs), insertions/deletions (INDELs), and copy number variations (CNVs). Exome-wide somatic reference standards were generated to support analytical validation using multiple sequencing runs of cell lines at varying purities.
RESULTS: Assay validation involves 3 steps: (1) analytical validation using custom reference samples containing 3042 SNVs and 47,466 CNVs; (2) orthogonal testing in patient samples; and (3) assessment of clinical utility in real-world cases. Applied to 2230 clinical tumor samples, the integrated assay enables direct correlation of somatic alterations with gene expression, recovery of variants missed by DNA-only testing, and improves detection of gene fusions. In addition to uncovering clinically actionable alterations in 98% of cases, the assay also reveals complex genomic rearrangements that would likely have remained undetected without RNA data.
CONCLUSIONS: This study provides practical validation guidelines for integrated RNA and DNA sequencing in clinical oncology. The combined assay enhances the detection of actionable alterations, thereby facilitating personalized treatment strategies for cancer patients.